Search results
Results From The WOW.Com Content Network
Top surgery involves more than a mastectomy for the treatment of breast cancer. [1] Special techniques are used to contour and reduce the chest wall, position the nipples and areola, and minimize scarring. [1] If the breast size is small, surgery that spares the skin, nipple and areola (subcutaneous nipple-sparing mastectomy) may be performed ...
v. t. e. Masculinizing hormone therapy, also known as transmasculine hormone therapy or female-to-male (or FTM) hormone therapy, is a form of hormone therapy and gender affirming therapy which is used to change the secondary sexual characteristics of transgender people from feminine or androgynous to masculine. [ 1][ 2][ 3] It is a common type ...
v. t. e. Gender-affirming surgery for male-to-female transgender women or transfeminine non-binary people describes a variety of surgical procedures that alter the body to provide physical traits more comfortable and affirming to an individual's gender identity and overall functioning. Often used to refer to vaginoplasty, sex reassignment ...
Gender-affirming surgery is a surgical procedure, or series of procedures, that alters a person's physical appearance and sexual characteristics to resemble those associated with their identified gender. The phrase is most often associated with transgender health care and intersex medical interventions, although many such treatments are also ...
Tumor marker. A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior of cancers (measure progression or response to therapy). They can be found in bodily fluids or tissue. Markers can help with assessing prognosis, surveilling patients after surgical removal of tumors, and even predicting drug-response ...
[337] [334] There is no evidence that breast cancer risk in transgender women is greater than in cisgender women. [338] Twenty cases of breast cancer in transgender women have been reported as of 2019. [334] [339] Cisgender men with gynecomastia have not been found to have an increased risk of breast cancer. [340]
Triple-negative breast cancer comprises 15–20% of all breast cancer cases [3] and affects more young women or women with a mutation in the BRCA1 gene than other breast cancers. [4] Triple-negative breast cancers comprise a very heterogeneous group of cancers. TNBC is the most challenging breast cancer type to treat. [5]
New or potentially new markers for breast cancer include BRCA1 and BRCA2 [197] to identify people at high risk of developing breast cancer, HER-2, [medical citation needed] and SCD1, for predicting response to therapeutic regimens, and urokinase plasminogen activator, PA1-1 and SCD1 for assessing prognosis.